Shandong Xinhua (00719) received the "Drug Supplement Application Approval Notice" for Rosuvastatin Calcium Tablets (20mg; 10mg)
Shandong Xinhua Pharmaceutical Co., Ltd. (00719) announced that recently, the company has received approval and issuance of the Ruishu...
SHANDONG XINHUA (00719) announced that recently the company received the approval notification from the National Medical Products Administration for the transfer of the marketing authorization application of rosuvastatin calcium tablets (20mg;10mg).
The rosuvastatin calcium tablets (20mg;10mg) were approved by the National Medical Products Administration in January 2025, and Shandong Xinhua Pharmaceutical became the marketing authorization holder for this product. The market launch of this product will help enrich the company's product line of statin lipid-regulating drugs and enhance the company's overall competitive advantage.
Related Articles
HANG SENG BANK (00011) spent approximately 23.7952 million Hong Kong dollars to repurchase 200,000 shares on September 18th.
Sanhui Integrated (603163.SH): Employee shareholding platform Suzhou Shengzhan plans to reduce its stake in the company by no more than 0.62%.
TIME WATCH (02033) issued a profit warning, anticipating an annual loss of HK$17 million for the company's shareholders compared to a profit.
HANG SENG BANK (00011) spent approximately 23.7952 million Hong Kong dollars to repurchase 200,000 shares on September 18th.
Sanhui Integrated (603163.SH): Employee shareholding platform Suzhou Shengzhan plans to reduce its stake in the company by no more than 0.62%.
TIME WATCH (02033) issued a profit warning, anticipating an annual loss of HK$17 million for the company's shareholders compared to a profit.
